IJCS | Volume 33, Nº4, July and August 2020

411 disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-67. 9. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-9. 10. Ji HL, Zhao R, Matalon S, Matthay MA. Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev. 2020;100(3):1065-75. 11. Atri D, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies. JACC Basic Transl Sci. 2020;5(5):518-36. 12. Li T, LuH, ZhangW. Clinical observation andmanagement of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687-90. 13. Li G, Hu R, Zhang X. Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension. Hypertens Res. 2020 Mar 30;43:588-90. 14. Abassi Z, Assady S, Khoury EE, Heyman SN. Angiotensin converting enzyme 2: an ally or a Trojan horse? Implications to SARS‐CoV‐2 ‐ related cardiovascular complications. Am J Physiol Heart Circ Physiol. 2020;318(5):H1080-83. 15. SouthAM, DizD, ChappellMC. COVID-19,ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084-90. 16. Ortega JT, Serrano ML, Pujol FH, Rangel HR. Role of changes in SARS- CoV-2 spike protein in the interaction with the human ACE2 receptor: an in silico analysis. EXCLI J. 2020 Mar 18;19:410-7. 17. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is there an association between COVID-19 mortality and the renin-angiotensin system - a Call for epidemiologic investigations. Clin Infect Dis. 2020 Mar 26. [Epub ahead of print]. 18. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin i in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020 Mar 10. [Epub ahead of print]. 19. GuanWJ,NiZY,HuY,LiangWH,OuCQ,HeJX,etal.Clinicalcharacteristics ofcoronavirusdisease2019inChina.NEnglJMed.2020Apr30;382:1708-20. 20. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin- converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc. 2020;9(7):e016219. 21. Solaimanzadeh I. Acetazolamide, nifedipine and phosphodiesterase inhibitors:rationalefortheirutilizationasadjunctivecountermeasuresinthe treatmentofcoronavirusdisease2019(COVID-19).Cureus.2020;12(3):e7343. Pedro et al. Cardiovascular pharmacotherapy and covid-19 Int J Cardiovasc Sci. 2020; 33(4):404-411 Viewpoint This is an open-access article distributed under the terms of the Creative Commons Attribution License